Research on the effect of sizing agent on the interface and compression performance of carbon fiber composites

Xinfeng Ouyang(University of Science and Technology Beijing), Kangmin Niu(University of Science and Technology Beijing), Yuefeng Bai(University of Science and Technology Beijing), Yangyang Zong(Shenzhen University), Yizhi Geng(University of Science and Technology Beijing), Shuo Duan(Chongqing Vocational and Technical University of Mechatronics), Xiao Wang(Qingdao University), Weiwei Zhu(Group Health Cooperative), T. Pan, Yunpeng Liu(Shenyang Institute of Automation), Guojie Ge
Frontiers in Materials
August 22, 2024
10.3389/fmats.2024.1437104
Cited by 11

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412